ZFIN ID: ZDB-PUB-121019-37
Investigations regarding the utility of prodigiosenes to treat leukemia
Smithen, D.A., Forrester, A.M., Corkery, D.P., Dellaire, G., Colpitts, J., McFarland, S.A., Berman, J.N., and Thompson, A.
Date: 2013
Source: Organic & biomolecular chemistry   11(1): 62-68 (Journal)
Registered Authors: Berman, Jason, Corkery, Dale, Forrester, Michael
Keywords: none
MeSH Terms:
  • Animals
  • Antineoplastic Agents/chemical synthesis
  • Antineoplastic Agents/chemistry
  • Antineoplastic Agents/pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation/drug effects
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Humans
  • Leukemia/drug therapy*
  • Leukemia/pathology
  • Molecular Structure
  • Neoplasms, Experimental/drug therapy*
  • Neoplasms, Experimental/pathology
  • Prodigiosin/analogs & derivatives
  • Prodigiosin/chemistry
  • Prodigiosin/pharmacology*
  • Pyrroles/chemical synthesis
  • Pyrroles/chemistry
  • Pyrroles/pharmacology*
  • Structure-Activity Relationship
  • Zebrafish
PubMed: 23070266 Full text @ Org. Biomol. Chem.

Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer cell line panel. Further in vivo studies of these compounds using the zebrafish model showed persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells.